Sangamo Biosciences, Inc. (NASDAQ:SGMO)
| CAPS Rating |
|
|---|---|
| Open | $4.27 |
| Previous Close | $4.32 |
| Daily Range | $4.18 - $4.36 |
| 52-Week Range | $2.36 - $9.15 |
| Market Cap | $222.45M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 341,069 |
| Average Daily Volume | 0 |
SGMO
VS S&P 500 (SPY)
How do you think SGMO will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
SGMO Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
SGMO News and Commentary
- Shire and Sangamo Cut a Deal - Analyst Blog – NASDAQ
- Sangamo BioSciences To Partner With Shire To Develop DNA Technology – SmartMoney
- Smart Money Picks: Biotech Stocks With Bullish Short Trends – The Motley Fool
- Rebound Candidates: Stocks Near Lows with Short Covering and Institutional Buying – NASDAQ
- Rebound Candidates: Stocks Near Lows With Short Covering and Institutional Buying – The Motley Fool
- Brain Disorders: 3 Biotech Stocks at the Forefront – NASDAQ
- Why Did My Stock Just Die? – The Motley Fool
- About That Developing Technology... – The Motley Fool
- Stocks Choppy; U.S. Manufacturing Data Show Modest Gains, Greece Weighs – NASDAQ
- Mid-Day Update: Stocks Fall as Greece Concerns Outweigh Economic Uptick – NASDAQ
- Sangamo Neuropathy Drug Failed to Meet Goal in Mid-Stage Trial – Fox Business
- Sangamo Dropping on Diabetic Drug Failure – Minyanville
- Are HIV Drugmakers Doomed? – The Motley Fool
- Sangamo Drops After Positive HIV Drug Study – Minyanville
- Sangamo Touts Cure for HIV – Minyanville
- Wall Street's Buy List – The Motley Fool
- Sangamo BioSciences' CEO Discusses Q2 2011 Results - Earnings Call Transcript – SeekingAlpha Transcripts
- UPDATE: Drug Firms, US Academia To Partner On HIV Projects – SmartMoney
- Sangamo BioSciences CEO Discusses Q1 2011 Results - Earnings Call Transcript – SeekingAlpha
- Sangamo BioSciences CEO Discusses Q1 2011 Results - Earnings Call Transcript – SeekingAlpha Transcripts
RSS Headlines
Fool UK
